Synonyms: MP 470 | MP-470 | MP470
Compound class:
Synthetic organic
Comment: Amuvatinib is an orally bioavailable, multitargeted receptor tyrosine kinase inhibitor. Some bioactivity data may be associated with the hydrochloride salt (PubChem CID 67254077).
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Bearss DJ, Joshi-Hangal R, Liu X-H, Phiasivongsa P, Redkar SG, Vankayalapati H, Az D. (2008)
Cell proliferation; anticancer agents; bioavailability. Patent number: US20080226747. Assignee: Supergen, Inc.. Priority date: 01/03/2007. Publication date: 18/09/2008. |
2. Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, Wisner L, Iorio M, Shakalya K, Garewal H et al.. (2007)
A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene, 26 (27): 3909-19. [PMID:17325667] |
3. Welsh JW, Mahadevan D, Ellsworth R, Cooke L, Bearss D, Stea B. (2009)
The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol, 4: 69. [PMID:20028557] |
4. Zhao H, Luoto KR, Meng AX, Bristow RG. (2011)
The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination. Radiother Oncol, 101 (1): 59-65. [PMID:21903282] |